- Tags: retina
Events
Registration opens for Eyes on Retina 2026
EOE’s virtual event of the year for retina-focused ECPs kicks off in October—with the chance to claim up to 5 hours of CE or CME.
Research
Maternal asthma may increase ROP risk
A new study found that preterm infants born to mothers with asthma had higher odds of developing treatment-warranted retinopathy of prematurity.
Pipeline
Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy
EYC-0305 is under evaluation as a potential long-acting treatment designed for 6-month or longer dosing intervals via IVT injection.
Pipeline
Sumitomo Pharma America doses first patient in RP cell therapy trial
Phase 1/2a trial evaluating DSP-3077 as a regenerative cell therapy is estimated to complete in October 2028.
Research
Eyedaptic AI smart glasses deliver 5.7-line acuity gain in AMD
Study demonstrates significant and immediate VA improvements in patients with advanced retinal disease.
Research
Rosacea may double risk for DR progression
Patients with rosacea and early-stage DR had more than twice the risk of progressing to proliferative disease—and a higher need for retinal intervention over 5 years.
Research
Atopic dermatitis linked to higher retinal detachment risk
Adults with eczema were nearly three times more likely to develop retinal detachment and had worse surgical outcomes after repair.
Research
NSAID use may lower AMD risk
Prescribed patients appear less likely for disease development, with the association observed across multiple AMD subtypes and several commonly used medications
Pipeline
4DMT reports new phase 2b gene therapy data for wet AMD
New 2-year data demonstrates an overall 78% treatment reduction in patients treated with 4D-150 compared to bimonthly 2 mg aflibercept.
Pipeline
Belite Bio presents updated phase 3 data on oral tinlarebant for Stargardt
Findings released at ASRS highlight an 80% reduction in key protein implicated in Stargardt disease after 2 years.
Products
EVOQ Technologies receives US patent for mobile retinal function testing
Patent protection covers the SmartERG, a full-field ERG/VEP system that delivers visual stimulation and wirelessly records ocular electrophysiological responses.
Products
FDA approves Outlook's LYTENAVA for wet AMD
The VEGF inhibitor is now the first and only on-label ophthalmic formulation of bevacizumab for wet AMD treatment.
Research
Real-world pegcetacoplan data shows VA benefits through 18 months
EHR and AI-based imaging analysis presented at ASRS demonstrates SYFOVRE advantages extending to GA patients with concomitant wet AMD.
Research
Mediterranean diet linked to slower AMD progression
Diet aherence associated with slower AMD progression at every disease stage, with specific food components mattering most depending on the stage.
Events
ASRS 2026: industry highlights and product innovations
Annual retina specialists meeting kicks off in Montreal with immersive, interactive experiences and technology showcases.
Events
ASRS 2026: your retina research rundown
Annual meeting of retina specialists kicks off in Montreal with updates on the latest clinical findings shaping the future of retina research.
Business
Tarsus acquires iRenix Medical, adds late-stage ocular antiseptic
Company to initiate a phase 3 trial on IRX-101, an ocular antiseptic alternative to povidone-iodine among retinal patients receiving IVT injections.
Products
Eyes On Eyecare launches retina research-based app
Cited for Retina offers a “PubMed meets Instagram Stories” way for retina specialists to discover, digest, and react to new research shaping their practice.
Pipeline
RegenxBio doses first patient in phase 2b/3 trial for DR
One-time gene therapy continues to move down the pipeline, with presentations on efficacy and safety data expected at ASRS.
Research